The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Subscribe To Our Newsletter & Stay Updated
